Trial: 202003170

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors

Phase

I

Principal Investigator

Van Tine, Brian

Disease Site

Lung; Soft Tissue

Learn more about this study at: clinicaltrials.gov